Head & Neck Cancers

December 1, 2020 - The FDA has approved pralsetinib for the treatment of select patients with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

November 13, 2020 - Treatment with the combination of eganelisib, a selective PI3K-γ inhibitor, and nivolumab demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma.

November 13, 2020 - ALX148 showcased favorable safety and elicited objective responses when combined with trastuzumab, pembrolizumab, and multiagent chemotherapy regimens in patients with gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma.

In our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.

Nabil F. Saba, MD, FACP, discusses ongoing clinical trials in head and neck cancer.

Alan L. Ho, MD, PhD, highlights the great strides that have been made with head and neck cancer, including those with rarer diseases like thyroid cancer and salivary gland cancers, due to a greater understanding of disease biology and genomics.

The investigational small molecule, γ-secretase inhibitor AL101 monotherapy was found to elicit deep responses with a significant disease control rate in patients with recurrent or metastatic adenoid cystic carcinoma harboring NOTCH activating mutations.

Investigators are testing tipifarnib, a novel drug that inhibits a critical enzyme needed for HRAS activation, in patients with head and neck squamous cell carcinoma whose tumors harbor the mutation.

Heavily pretreated patients with unresectable recurrent or metastatic head and neck squamous cancer experienced an improvement in survival following treatment with axitinib.

Ezra Cohen, MD, FRCPSC, FASCO, discusses the design of the phase 2 SPEARHEAD-2 trial with ADP-A2M4 plus pembrolizumab in patients with recurrent or metastatic head and neck cancer.

Dana-Farber Cancer Institute has launched the Center for Salivary and Rare Head and Neck Cancers to treat patients with rare and occasionally aggressive cancers arising from the head and neck.

Yale Cancer Center researchers were awarded a five-year, $11.7 million grant from the National Institutes of Health to fund the Yale Head and Neck Cancer Specialized Program of Research Excellence.

Potent and durable clinical activity was shown with pralsetinib as treatment of patients with RET-mutant advanced medullary thyroid cancer, regardless of the line of therapy.

Three-year follow-up data for the phase 2 study of the first-in-class inhibitor of apoptosis protein antagonist, xevinapant, in combination with standard cisplatin-based concomitant fractionation chemoradiation therapy reduced the risk of mortality by half compared with CRT alone in patients with locally advanced squamous cell carcinoma of the head and neck.

The FDA has granted pralsetinib a priority review for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion–positive thyroid cancer.

Robert L. Ferris, MD, PhD, discusses the safety profile of transoral robotic surgical resection in oropharynx cancer.

Tipifarnib demonstrated encouraging antitumor activity in patients with recurrent and metastatic head and neck cancer with high HRAS-mutant variant allele frequency, surpassing historical competitors in the second- or later-line settings.

Debio 1143 in combination with standard cisplatin-based concomitant fractionation chemoradiation therapy was found to induce a statistically and clinically significant improvement in overall survival compared with CRT alone in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.

A new drug application has been submitted to the FDA for pralsetinib (BLU-667) for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion–positive thyroid cancers.

In our exclusive interview, Everett Vokes, MD, discusses the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.

The FDA has approved an expanded indication for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus types 16, 18, 31, 33, 45, 52, and 58.

The FDA has approved selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.

Hoping to minimize the off-target effects associated with radiation in patients with oropharyngeal cancer, investigators are testing the hypothesis that intensitymodulated proton therapy can deliver doses as effectively as the current standard of care with less damage to surrounding tissue.